Literature DB >> 2295384

Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel syndrome.

R C Smith1, D S Greenbaum, J B Vancouver, R C Henry, M A Reinhart, R B Greenbaum, H A Dean, J E Mayle.   

Abstract

The objective of this prospective study was to test the hypothesis that 6 reportedly important psychosocial factors were useful criteria for diagnosing the irritable bowel syndrome. Ninety-seven new patients with entry complaints of abdominal pain, altered bowel habits, or both underwent full evaluation by board-certified or -eligible gastroenterologists in an outpatient setting. The independent measures were 6 questionnaires concerning anxiety, depression, stress, lack of social support, somatization, and abnormal illness behavior. The dependent measure, irritable bowel syndrome, was defined as the absence of an organic disease explanation for patients' entry complaints. Two other board-certified gastroenterologists, independent of the study, made this determination. Their rating was based on full review of transcripts of patients' clinic visits, laboratory data, and the results of a 9-mo telephone follow-up to patients and their physicians. Sixty-five percent of the sample had no organic disease explanation for the entry symptoms, thereby representing irritable bowel syndrome. The psychosocial predictors did not show a significant association with irritable bowel syndrome; the power of the study was 0.86. Post hoc analysis revealed that patients with organic disease, as well as patients with irritable bowel syndrome, had significantly more (p less than 0.01) psychosocial abnormality than normal subjects, which likely contributed to the inability of the psychosocial predictors to distinguish irritable bowel syndrome from organic disease. It was concluded that psychosocial criteria were of limited value in differentiating irritable bowel syndrome from organic disease but that they were determinants of health care seeking for the entire study group.

Entities:  

Mesh:

Year:  1990        PMID: 2295384     DOI: 10.1016/0016-5085(90)90817-k

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

1.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

2.  Diagnosing irritable bowel syndrome: what's too much, what's enough?

Authors:  Susan Lucak
Journal:  MedGenMed       Date:  2004-03-12

Review 3.  Somatization disorder: defining its role in clinical medicine.

Authors:  R C Smith
Journal:  J Gen Intern Med       Date:  1991 Mar-Apr       Impact factor: 5.128

4.  Chronic diarrhoea.

Authors:  R Spiller
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

Review 5.  Current views on the aetiology and management of the irritable bowel syndrome.

Authors:  M J Hall; R E Barry
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

6.  Recurrent abdominal pain: what determines medical consulting behavior?

Authors:  Neeta Kiran Venepalli; Miranda A L Van Tilburg; William E Whitehead
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

7.  Health care seeking for abdominal bloating and visible distention.

Authors:  X Jiang; G R Locke; A R Zinsmeister; C D Schleck; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2009-06-25       Impact factor: 8.171

8.  Rectal bleeding: prevalence and consultation behaviour.

Authors:  A Crosland; R Jones
Journal:  BMJ       Date:  1995-08-19

9.  Assessment of functional gastrointestinal disorders using the Gastro-Questionnaire.

Authors:  Rolf Leibbrand; Ulrich Cuntz; Wolfgang Hiller
Journal:  Int J Behav Med       Date:  2002

10.  Psychological aspects of irritable bowel syndrome.

Authors:  M Rajagopalan; G Kurian; J K John
Journal:  Indian J Psychiatry       Date:  1996-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.